



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 17 Sep 2018 (#27)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices

- **NIH & AHRQ Announce Upcoming Updates to Application Instructions and Review Criteria for Research Grant Applications ([NOT-OD-18-228](#))**

The purpose of this Notice is to inform the biomedical and health services research communities of planned updates to application instructions and review criteria language for research grant applications submitted for **due dates on or after January 25, 2019**. The planned updates include changes to the following areas:

 - The rigor of the prior research, formerly Scientific Premise (Note: Please refer to [NOT-OD-16-011](#) for a list of activity codes excluded from the Enhancing Reproducibility policy)
 - Inclusion reporting
 - Protections for human subjects
- **NIH & AHRQ Announce Upcoming Updates to Application Instructions and Review Criteria for Career Development Award Applications ([NOT-OD-18-229](#))**

The purpose of this Notice is to inform the biomedical and health services research communities of planned updates to application instructions and review criteria language for career development award applications submitted for due dates on or after **January 25, 2019**. The planned updates focus on the following areas:

 - The rigor of the prior research, formerly Scientific Premise (Note: K02, K05, and K24 career development award activity codes are excluded from the Enhancing Reproducibility policy)
 - Inclusion reporting
 - Protections for human subjects
- **Development of New Antibacterial Drugs Active Against Multi-Drug Resistant Bacteria ([NOT-FD-18-016](#)) Food and Drug Administration.**

The purpose of this Request for Information (RFI) is to solicit informal input from the public and private sectors (e.g. industry, academia, Federally Funded Research and Development Centers (FFRDCs), government laboratories, physician and pharmacist societies, patient-focused research foundations and advocacy groups, and other health care providers) to obtain external input into developing an annual list of regulatory science initiatives specific for antimicrobial products. This input will help the Office of Antimicrobial Products develop the FY2019 Regulatory Science Initiatives. This RFI seeks research ideas to identify research areas where regulatory science can support new antibacterial drug development in general, by creating new drug development tools or standards for use by industry or other stakeholders, to meet patient needs.
- **Notice of Intent to Publish a Funding Opportunity Announcement for NINDS Exploratory Grant for Morris K. Udall Center without Walls for Parkinsons Disease Research (P20) ([NOT-NS-18-083](#)) National Institute of Neurological Disorders and Stroke**

The purpose of this FOA for Exploratory Grant (P20) applications is to support the formation of new, highly skilled research consortia to address urgent and emergent challenges posed by the inherent complexity of Parkinson's Disease

(PD). Resolution of some particularly difficult challenges requires a transdisciplinary "Center without Walls (CWOW)" approach, in which a specialized research consortium works seamlessly across institutional, geographic and research boundaries using a goal-driven approach to resolve an essential question or controversy in PD.

- Estimated Publication Date of Funding Opportunity Announcement: October 01, 2018
- First Estimated Application Due Date: December 14, 2018

- Notice of Change to the **Eligibility of Foreign Components** in [PA-18-060](#) and [PA-18-078](#) "**Neuroscience Research on Drug Abuse**" (R01) ([NOT-DA-18-042](#)) and (R21) ([NOT-DA-18-043](#))

Modified to read: Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

1. Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(RFA-DK-18-017\)](#)

Type: R01

Application Due Date: February 21, 2019. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: National Institute of Diabetes and Digestive and Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified about 200 susceptibility loci for IBD. The IBDGC has recently been awarded renewed funding to identify causal genes and genetic variants within these loci, and to elucidate the mechanisms through which they contribute to the pathophysiology of IBD. However, the IBDGC's current resources permit them to explore the functions of only a limited set of genes within a limited set of physiological domains. The purpose of this Funding Opportunity Announcement (FOA) is to expand the number of genes and range of IBD-related phenotypes and physiological domains under study by means of collaborations of the IBDGC with investigators with expertise complementary to that of their own members. Proposed studies must not duplicate studies either ongoing or already completed by the IBDGC. Multi-site clinical trials will not be considered responsive to this FOA.

Budget: NIDDK intends to commit up to \$1,000,000 in FY 2019 to fund up to 3 awards. Application budgets are limited to \$200,000 direct costs per year. The maximum project period is 3 years.

2. AIDS-Science Track Award for Research Transition (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-916\)](#)

Type: R03

Application Due Date: [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug misuse and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating drug misuse and/or use disorder and HIV/AIDS across all areas of research supported by National Institute on Drug Abuse (NIDA).

Budget: Budgets for direct costs of up to \$50,000 per year may be requested. The project period is limited to two years.

3. Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-917\)](#)

Type: R01

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Imaging - Science Track Award for Research Transition (I/START) (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-918\)](#)

Type: R03

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This funding opportunity announcement (FOA) encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources.

Budget: Budgets for direct costs of up to \$150,000 per year and is for a period of one year only. The maximum project period is 1 year.

5. Quantitative Imaging Tools and Methods for Cancer Response Assessment (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-919\)](#)

Type: *R01*

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging software tools for planning and validating radiation therapy treatment strategies in clinical trials. The quantitative software tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those software tools in prospective multisite clinical trials to test software tool performance and to demonstrate that the software tool can be integrated into clinical workflow with a minimum of disruption.

Budget: Application budgets need to reflect the actual needs of the proposed project. Budget requests cannot exceed \$500,000 in direct costs for each proposed year. The maximum project period is 5 years.

6. HIV/AIDS High Priority Drug Abuse Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAS-18-915\)](#)

Type: *R01*

Application Due Date: [Standard dates](#) & [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health has recently announced the HIV/AIDS research priorities for the next three to five years <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html>. The goal of this Funding Opportunity Announcement (FOA) is to stimulate high priority research relevant to drug misuse and HIV/AIDS.

Budget: Application budgets need to reflect the actual needs of the proposed project. Budget requests cannot exceed \$500,000 in direct costs for each proposed year. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)